While only a few studies have looked into the role of mutant mast cells in CH, mutations in DNMT3A, TET2, or ASXL1 were shown to affect the prognosis and reduce the overall survival of patients with mastocytosis, a hematological neoplasm with aberrant accumulation of mast cells in multiple organs [75,76]. Here, TET2 is linked to cyclic hematopoiesis.